A van Hylckama Vlieg1, C A Baglin2, R Luddington2, S MacDonald2, F R Rosendaal1,3, T P Baglin2. 1. Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, the Netherlands. 2. Department of Heamatology, Addenbrookes Hospital, Cambridge, UK. 3. Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, the Netherlands.
Abstract
BACKGROUND: D-dimer and thrombin generation have been associated with the risk of recurrent venous thrombosis. However, for both measurements, different assays are available, and in vitro thrombin generation may be affected by the problem of contact activation during blood sampling. OBJECTIVES: To determine the association between hypercoagulability and first and recurrent thrombosis by the use of different D-dimer and thrombin generation assays, to assess whether the addition of corn trypsin inhibitor (CTI) prior to blood sampling to inhibit contact activation improved the association between thrombin generation and thrombosis risk, and to calculate the DASH score with two different D-dimer assays. METHODS: A case-control study (626 patients and 361 controls) with subsequent follow-up of the cases was performed (2987 patient-years after stopping of anticoagulant therapy). Blood was drawn 2-3 months after discontinuation of anticoagulation for the first event in citrate tubes with and without CTI. RESULTS/ CONCLUSIONS: An elevated D-dimer level and elevated thrombin generation were associated with an increased risk of a first event regardless of the assay used (odds ratios: 1.8-3.4). An elevated D-dimer level but not elevated thrombin generation was associated with the risk of recurrence. Patients with elevated D-dimer levels had a more than two-fold increased recurrence rate (Vidas - hazard ratio [HR] 2.3, 95% confidence interval [CI] 1.4-3.8; HemosIL - HR 2.4, 95% CI 1.5-3.9; Thrombinoscope and Technoclone assay - HR 1.3). Elimination of contact factor activation did not improve the predictive value of thrombin generation. In patients with unprovoked first events, the DASH score had a similar predictive value for deep vein thrombosis and pulmonary embolism, both when calculated with Vidas D-dimer and when calculated with HemosIL D-dimer.
BACKGROUND: D-dimer and thrombin generation have been associated with the risk of recurrent venous thrombosis. However, for both measurements, different assays are available, and in vitro thrombin generation may be affected by the problem of contact activation during blood sampling. OBJECTIVES: To determine the association between hypercoagulability and first and recurrent thrombosis by the use of different D-dimer and thrombin generation assays, to assess whether the addition of corn trypsin inhibitor (CTI) prior to blood sampling to inhibit contact activation improved the association between thrombin generation and thrombosis risk, and to calculate the DASH score with two different D-dimer assays. METHODS: A case-control study (626 patients and 361 controls) with subsequent follow-up of the cases was performed (2987 patient-years after stopping of anticoagulant therapy). Blood was drawn 2-3 months after discontinuation of anticoagulation for the first event in citrate tubes with and without CTI. RESULTS/ CONCLUSIONS: An elevated D-dimer level and elevated thrombin generation were associated with an increased risk of a first event regardless of the assay used (odds ratios: 1.8-3.4). An elevated D-dimer level but not elevated thrombin generation was associated with the risk of recurrence. Patients with elevated D-dimer levels had a more than two-fold increased recurrence rate (Vidas - hazard ratio [HR] 2.3, 95% confidence interval [CI] 1.4-3.8; HemosIL - HR 2.4, 95% CI 1.5-3.9; Thrombinoscope and Technoclone assay - HR 1.3). Elimination of contact factor activation did not improve the predictive value of thrombin generation. In patients with unprovoked first events, the DASH score had a similar predictive value for deep vein thrombosis and pulmonary embolism, both when calculated with Vidas D-dimer and when calculated with HemosIL D-dimer.
Authors: Abdullah Pandor; Daniel Horner; Sarah Davis; Steve Goodacre; John W Stevens; Mark Clowes; Beverley J Hunt; Tim Nokes; Jonathan Keenan; Kerstin de Wit Journal: Health Technol Assess Date: 2019-12 Impact factor: 4.014
Authors: S B Jensen; K Hindberg; T Solomon; E N Smith; J D Lapek; D J Gonzalez; N Latysheva; K A Frazer; S K Braekkan; J-B Hansen Journal: J Thromb Haemost Date: 2018-08-06 Impact factor: 5.824
Authors: Amanda P Waller; Jonathan P Troost; Samir V Parikh; Katelyn J Wolfgang; Brad H Rovin; Marvin T Nieman; William E Smoyer; Matthias Kretzler; Bryce A Kerlin Journal: Thromb Res Date: 2021-02-16 Impact factor: 3.944
Authors: Tariq Faquih; Dennis O Mook-Kanamori; Frits R Rosendaal; Trevor Baglin; Ko Willems van Dijk; Astrid van Hylckama Vlieg Journal: Res Pract Thromb Haemost Date: 2021-05-04
Authors: Banne Nemeth; Raymond A van Adrichem; Astrid van Hylckama Vlieg; Paolo Bucciarelli; Ida Martinelli; Trevor Baglin; Frits R Rosendaal; Saskia le Cessie; Suzanne C Cannegieter Journal: PLoS Med Date: 2015-11-10 Impact factor: 11.069
Authors: Ellen G Driever; R Todd Stravitz; Jingwen Zhang; Jelle Adelmeijer; Valerie Durkalski; William M Lee; Ton Lisman Journal: Hepatology Date: 2021-05 Impact factor: 17.425